Fig. 3
From: Inhibition of hexokinases holds potential as treatment strategy for rheumatoid arthritis
Treatment of HKs inhibitor, lonidamine, with RASFs. RASFs (n = 3) were treated with LND (100 μM) or its vehicle for 24 h, glucose uptake (a), HKs activity (b), glucose consumption (c), and l-lactate level (d) were determined. MTS and Annexin X staining were applied to detect the cell viability (e) and apoptosis (f) of RASFs (n = 3). The statistical significance of differences between LND- and vehicle-treated groups was determined. Data represent the mean ± SE. *p < 0.05, **p < 0.01 significantly different